The AMDHD2 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HeLa cell line, designed to disrupt the AMDHD2 gene. This product consists of a heterogeneous pool of cells harboring diverse mutations at the targeted locus, resulting from non-clonal selection after Cas9-mediated gene disruption. Unlike monoclonal isolates, this polyclonal format captures a spectrum of genetic perturbations, offering a robust loss-of-function model that reflects population-level gene inactivation. The absence of a clonal bottleneck helps preserve biological variance and is well-suited for experiments where pooled genetic perturbation is desirable, such as functional screens or studies requiring a broad representation of knockout phenotypes.
HeLa cells are a well-established immortalized epithelial cell line originating from a cervical adenocarcinoma and are widely employed as a model system in cancer biology. These cells are persistently infected with human papillomavirus type 18 (HPV-18), leading to constitutive expression of the E6 and E7 oncoproteins. E6 promotes the ubiquitin-mediated degradation of the tumor suppressor p53, while E7 binds and inactivates the retinoblastoma protein (Rb), resulting in deregulated cell cycle progression and compromised DNA damage checkpoints. This HPV-transformed background is highly relevant for studying gene perturbations that may intersect with or bypass these canonical oncogenic pathways, and it provides a tumorigenic context for functional assays.
AMDHD2 encodes a protein predicted to belong to the amidohydrolase superfamily, which catalyzes the hydrolysis of carbon-nitrogen bonds in a range of substrates. Although its specific enzymatic activity and physiological substrates remain uncharacterized, AMDHD2 is presumed to participate in metabolic regulation and has been linked to pathways of chromatin modification and gene expression. The exact upstream regulators, downstream targets, and interacting partners of AMDHD2 are currently unknown; thus, its mechanistic role is inferred from its sequence homology and preliminary studies suggesting a potential influence on metabolic and transcriptional networks. The polyclonal knockout of AMDHD2 in HeLa cells is anticipated to disrupt these putative functions, providing a tool to probe its biological significance in a cell-based system.
In the context of HPV-positive cervical adenocarcinoma cells with defective p53 and Rb pathways, the loss of AMDHD2 function may unveil specific vulnerabilities or adaptive responses pertinent to cancer cell metabolism and epigenetics. The polyclonal nature of this knockout population allows for the detection of robust phenotypes that are consistent across multiple independent editing events, while also enabling the isolation of discrete subpopulations if single-cell-derived clones are required for downstream analyses. This model is especially valuable for investigating the role of amidohydrolase family members in tumor biology, given the altered metabolic demands and epigenetic landscapes of cancer cells.
Researchers can apply this product in a variety of experimental settings. Suggested applications include functional characterization of AMDHD2 by western blotting to verify loss of protein expression, RT-qPCR to measure transcriptional effects, and RNA-sequencing to assess genome-wide transcriptomic changes. Cell-based assays such as proliferation, apoptosis, and metabolic profiling can be employed to evaluate phenotypic outcomes. The use of appropriate wild-type HeLa or non-targeting sgRNA control cells is essential for rigorous interpretation. For further details, technical inquiry, or custom genome editing services, please contact Ascent Research.
